Do analysts prefer CDT or ALVR?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CDT Equity 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 AlloVir 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher earnings & valuation, CDT or ALVR?

AlloVir is trading at a lower price-to-earnings ratio than CDT Equity, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CDT Equity N/A N/A -$39.22M -$66.34 thousand N/A AlloVir N/A N/A -$190.42M -$20.23 N/A

Is CDT or ALVR more profitable?

AlloVir's return on equity of -71.03% beat CDT Equity's return on equity. Company Net Margins Return on Equity Return on Assets CDT Equity N/A -4,263.33% -529.91% AlloVir N/A -71.03% -61.27%

Do analysts rate CDT or QUCY?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CDT Equity 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Mainz Biomed 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Which has higher earnings and valuation, CDT or QUCY?

Mainz Biomed has higher revenue and earnings than CDT Equity. Mainz Biomed is trading at a lower price-to-earnings ratio than CDT Equity, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CDT Equity N/A N/A -$39.22M -$66.34 thousand N/A Mainz Biomed $540K 39.50 -$16.21M -$47.60 N/A

Is CDT or QUCY more profitable?

Mainz Biomed's return on equity of 0.00% beat CDT Equity's return on equity. Company Net Margins Return on Equity Return on Assets CDT Equity N/A -4,263.33% -529.91% Mainz Biomed N/A N/A N/A

Does the media favor CDT or QUCY?

In the previous week, CDT Equity had 4 more articles in the media than Mainz Biomed. MarketBeat recorded 7 mentions for CDT Equity and 3 mentions for Mainz Biomed. CDT Equity's average media sentiment score of 0.50 beat Mainz Biomed's score of 0.00 indicating that CDT Equity is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CDT Equity 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mainz Biomed 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate CDT or VYNE?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CDT Equity 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 VYNE Therapeutics 1 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.75

Which has stronger valuation and earnings, CDT or VYNE?

VYNE Therapeutics has higher revenue and earnings than CDT Equity. VYNE Therapeutics is trading at a lower price-to-earnings ratio than CDT Equity, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CDT Equity N/A N/A -$39.22M -$66.34 thousand N/A VYNE Therapeutics $570K 38.07 -$26.48M -$0.38 N/A

Is CDT or VYNE more profitable?

CDT Equity has a net margin of 0.00% compared to VYNE Therapeutics' net margin of -4,726.21%. VYNE Therapeutics' return on equity of -70.42% beat CDT Equity's return on equity. Company Net Margins Return on Equity Return on Assets CDT Equity N/A -4,263.33% -529.91% VYNE Therapeutics -4,726.21% -70.42% -63.46%

Do analysts prefer ALLR or CDT?

Allarity Therapeutics currently has a consensus target price of $10.25, indicating a potential upside of 688.46%. Given Allarity Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Allarity Therapeutics is more favorable than CDT Equity. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Allarity Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 CDT Equity 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ALLR or CDT more profitable?

Allarity Therapeutics' return on equity of -109.94% beat CDT Equity's return on equity. Company Net Margins Return on Equity Return on Assets Allarity Therapeutics N/A -109.94% -47.27% CDT Equity N/A -4,263.33% -529.91%

Does the media favor ALLR or CDT?

In the previous week, CDT Equity had 6 more articles in the media than Allarity Therapeutics. MarketBeat recorded 7 mentions for CDT Equity and 1 mentions for Allarity Therapeutics. CDT Equity's average media sentiment score of 0.50 beat Allarity Therapeutics' score of 0.50 indicating that CDT Equity is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Allarity Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CDT Equity 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer CDT or LPCN?

Lipocine has a consensus target price of $15.00, suggesting a potential upside of 507.29%. Given Lipocine's stronger consensus rating and higher possible upside, analysts plainly believe Lipocine is more favorable than CDT Equity. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CDT Equity 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Lipocine 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.33

Which has better valuation and earnings, CDT or LPCN?

Lipocine has higher revenue and earnings than CDT Equity. Lipocine is trading at a lower price-to-earnings ratio than CDT Equity, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CDT Equity N/A N/A -$39.22M -$66.34 thousand N/A Lipocine $1.98M 10.28 -$9.63M -$1.88 N/A

Is CDT or LPCN more profitable?

CDT Equity has a net margin of 0.00% compared to Lipocine's net margin of -571.18%. Lipocine's return on equity of -66.70% beat CDT Equity's return on equity. Company Net Margins Return on Equity Return on Assets CDT Equity N/A -4,263.33% -529.91% Lipocine -571.18% -66.70% -59.39%

Does the media favor CDT or LPCN?

In the previous week, CDT Equity had 6 more articles in the media than Lipocine. MarketBeat recorded 7 mentions for CDT Equity and 1 mentions for Lipocine. CDT Equity's average media sentiment score of 0.50 beat Lipocine's score of 0.00 indicating that CDT Equity is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CDT Equity 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lipocine 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

CDT Equity (CDT) Competitors

$1.09 -0.06 (-5.22%)

Closing price 06/24/2026 04:00 PM Eastern

Extended Trading

$0.96 -0.13 (-11.47%)

As of 06:39 AM Eastern

Compare

CDT vs. ALVR, QUCY, VYNE, ALLR, and LPCN

Should you buy CDT Equity stock or one of its competitors? MarketBeat compares CDT Equity with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with CDT Equity include AlloVir (ALVR), Mainz Biomed (QUCY), VYNE Therapeutics (VYNE), Allarity Therapeutics (ALLR), and Lipocine (LPCN). These companies are all part of the "pharmaceutical products" industry.

How does CDT Equity compare to AlloVir?

CDT Equity (NASDAQ:CDT) and AlloVir (NASDAQ:ALVR) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, profitability, earnings, dividends, media sentiment, valuation, risk and analyst recommendations.

3.3% of CDT Equity shares are owned by institutional investors. Comparatively, 66.1% of AlloVir shares are owned by institutional investors. 10.8% of CDT Equity shares are owned by company insiders. Comparatively, 32.1% of AlloVir shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

AlloVir's return on equity of -71.03% beat CDT Equity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CDT Equity	N/A	-4,263.33%	-529.91%
AlloVir	N/A	-71.03%	-61.27%

In the previous week, CDT Equity had 7 more articles in the media than AlloVir. MarketBeat recorded 7 mentions for CDT Equity and 0 mentions for AlloVir. CDT Equity's average media sentiment score of 0.50 beat AlloVir's score of 0.00 indicating that CDT Equity is being referred to more favorably in the media.

Company	Overall Sentiment
CDT Equity	Positive
AlloVir	Neutral

CDT Equity has a beta of 1.44, suggesting that its stock price is 44% more volatile than the broader market. Comparatively, AlloVir has a beta of 0.63, suggesting that its stock price is 37% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CDT Equity	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
AlloVir	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

AlloVir is trading at a lower price-to-earnings ratio than CDT Equity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CDT Equity	N/A	N/A	-$39.22M	-$66.34 thousand	N/A
AlloVir	N/A	N/A	-$190.42M	-$20.23	N/A

Summary

CDT Equity beats AlloVir on 6 of the 11 factors compared between the two stocks.

How does CDT Equity compare to Mainz Biomed?

CDT Equity (NASDAQ:CDT) and Mainz Biomed (NASDAQ:QUCY) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, risk, earnings, institutional ownership, dividends, analyst recommendations, valuation and profitability.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CDT Equity	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Mainz Biomed	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

In the previous week, CDT Equity had 4 more articles in the media than Mainz Biomed. MarketBeat recorded 7 mentions for CDT Equity and 3 mentions for Mainz Biomed. CDT Equity's average media sentiment score of 0.50 beat Mainz Biomed's score of 0.00 indicating that CDT Equity is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CDT Equity	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Mainz Biomed	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Mainz Biomed's return on equity of 0.00% beat CDT Equity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CDT Equity	N/A	-4,263.33%	-529.91%
Mainz Biomed	N/A	N/A	N/A

CDT Equity has a beta of 1.44, indicating that its stock price is 44% more volatile than the broader market. Comparatively, Mainz Biomed has a beta of 2.22, indicating that its stock price is 122% more volatile than the broader market.

Mainz Biomed has higher revenue and earnings than CDT Equity. Mainz Biomed is trading at a lower price-to-earnings ratio than CDT Equity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CDT Equity	N/A	N/A	-$39.22M	-$66.34 thousand	N/A
Mainz Biomed	$540K	39.50	-$16.21M	-$47.60	N/A

3.3% of CDT Equity shares are held by institutional investors. 10.8% of CDT Equity shares are held by insiders. Comparatively, 3.1% of Mainz Biomed shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Mainz Biomed beats CDT Equity on 7 of the 12 factors compared between the two stocks.

How does CDT Equity compare to VYNE Therapeutics?

CDT Equity (NASDAQ:CDT) and VYNE Therapeutics (NASDAQ:VYNE) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, risk, earnings, institutional ownership, media sentiment, analyst recommendations, profitability and dividends.

3.3% of CDT Equity shares are held by institutional investors. Comparatively, 83.8% of VYNE Therapeutics shares are held by institutional investors. 10.8% of CDT Equity shares are held by insiders. Comparatively, 3.0% of VYNE Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CDT Equity	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
VYNE Therapeutics	1 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75

CDT Equity has a beta of 1.44, indicating that its share price is 44% more volatile than the broader market. Comparatively, VYNE Therapeutics has a beta of 2, indicating that its share price is 100% more volatile than the broader market.

VYNE Therapeutics has higher revenue and earnings than CDT Equity. VYNE Therapeutics is trading at a lower price-to-earnings ratio than CDT Equity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CDT Equity	N/A	N/A	-$39.22M	-$66.34 thousand	N/A
VYNE Therapeutics	$570K	38.07	-$26.48M	-$0.38	N/A

In the previous week, CDT Equity had 7 more articles in the media than VYNE Therapeutics. MarketBeat recorded 7 mentions for CDT Equity and 0 mentions for VYNE Therapeutics. CDT Equity's average media sentiment score of 0.50 beat VYNE Therapeutics' score of 0.00 indicating that CDT Equity is being referred to more favorably in the media.

Company	Overall Sentiment
CDT Equity	Positive
VYNE Therapeutics	Neutral

CDT Equity has a net margin of 0.00% compared to VYNE Therapeutics' net margin of -4,726.21%. VYNE Therapeutics' return on equity of -70.42% beat CDT Equity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CDT Equity	N/A	-4,263.33%	-529.91%
VYNE Therapeutics	-4,726.21%	-70.42%	-63.46%

Summary

VYNE Therapeutics beats CDT Equity on 8 of the 13 factors compared between the two stocks.

How does CDT Equity compare to Allarity Therapeutics?

Allarity Therapeutics (NASDAQ:ALLR) and CDT Equity (NASDAQ:CDT) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, risk, earnings, valuation, institutional ownership and media sentiment.

Allarity Therapeutics has a beta of 0.52, suggesting that its stock price is 48% less volatile than the broader market. Comparatively, CDT Equity has a beta of 1.44, suggesting that its stock price is 44% more volatile than the broader market.

Allarity Therapeutics has higher revenue and earnings than CDT Equity. Allarity Therapeutics is trading at a lower price-to-earnings ratio than CDT Equity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Allarity Therapeutics	$320K	64.63	-$11.23M	-$0.72	N/A
CDT Equity	N/A	N/A	-$39.22M	-$66.34 thousand	N/A

11.5% of Allarity Therapeutics shares are held by institutional investors. Comparatively, 3.3% of CDT Equity shares are held by institutional investors. 0.2% of Allarity Therapeutics shares are held by insiders. Comparatively, 10.8% of CDT Equity shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, CDT Equity had 6 more articles in the media than Allarity Therapeutics. MarketBeat recorded 7 mentions for CDT Equity and 1 mentions for Allarity Therapeutics. CDT Equity's average media sentiment score of 0.50 beat Allarity Therapeutics' score of 0.50 indicating that CDT Equity is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Allarity Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CDT Equity	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Allarity Therapeutics' return on equity of -109.94% beat CDT Equity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Allarity Therapeutics	N/A	-109.94%	-47.27%
CDT Equity	N/A	-4,263.33%	-529.91%

Allarity Therapeutics currently has a consensus target price of $10.25, indicating a potential upside of 688.46%. Given Allarity Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Allarity Therapeutics is more favorable than CDT Equity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Allarity Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
CDT Equity	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Allarity Therapeutics beats CDT Equity on 9 of the 14 factors compared between the two stocks.

How does CDT Equity compare to Lipocine?

CDT Equity (NASDAQ:CDT) and Lipocine (NASDAQ:LPCN) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, institutional ownership, dividends, analyst recommendations, risk and earnings.

CDT Equity has a beta of 1.44, suggesting that its share price is 44% more volatile than the broader market. Comparatively, Lipocine has a beta of 0.48, suggesting that its share price is 52% less volatile than the broader market.

Lipocine has a consensus target price of $15.00, suggesting a potential upside of 507.29%. Given Lipocine's stronger consensus rating and higher possible upside, analysts plainly believe Lipocine is more favorable than CDT Equity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CDT Equity	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Lipocine	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33

3.3% of CDT Equity shares are held by institutional investors. Comparatively, 9.1% of Lipocine shares are held by institutional investors. 10.8% of CDT Equity shares are held by insiders. Comparatively, 6.4% of Lipocine shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, CDT Equity had 6 more articles in the media than Lipocine. MarketBeat recorded 7 mentions for CDT Equity and 1 mentions for Lipocine. CDT Equity's average media sentiment score of 0.50 beat Lipocine's score of 0.00 indicating that CDT Equity is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CDT Equity	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lipocine	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

CDT Equity has a net margin of 0.00% compared to Lipocine's net margin of -571.18%. Lipocine's return on equity of -66.70% beat CDT Equity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CDT Equity	N/A	-4,263.33%	-529.91%
Lipocine	-571.18%	-66.70%	-59.39%

Lipocine has higher revenue and earnings than CDT Equity. Lipocine is trading at a lower price-to-earnings ratio than CDT Equity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CDT Equity	N/A	N/A	-$39.22M	-$66.34 thousand	N/A
Lipocine	$1.98M	10.28	-$9.63M	-$1.88	N/A

Summary

Lipocine beats CDT Equity on 9 of the 15 factors compared between the two stocks.

Get CDT Equity News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CDT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CDT vs. The Competition

Export

Metric	CDT Equity	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$5.59M	$2.99B	$6.74B	$12.32B
Dividend Yield	N/A	1.78%	2.68%	5.88%
P/E Ratio	0.00	18.65	25.14	23.95
Price / Sales	N/A	341.96	534.57	107.90
Price / Cash	N/A	56.64	45.29	53.76
Price / Book	-0.01	4.14	10.79	6.41
Net Income	-$39.22M	$64.45M	$3.56B	$337.14M
7 Day Performance	6.86%	1.22%	0.99%	-1.07%
1 Month Performance	3.81%	0.95%	0.80%	0.48%
1 Year Performance	-99.78%	25.22%	30.27%	28.42%

CDT Equity Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CDT CDT Equity	0.6656 of 5 stars	$1.09 -5.2%	N/A	-99.8%	$5.59M	N/A	N/A	3	Gap Down
ALVR AlloVir	N/A	$4.40 -6.8%	N/A	+89.4%	$22.19M	N/A	N/A	110	High Trading Volume
QUCY Mainz Biomed	0.3947 of 5 stars	$1.49 -3.2%	N/A	N/A	$21.84M	$540K	N/A	30
VYNE VYNE Therapeutics	0.9501 of 5 stars	$0.65 flat	N/A	-38.6%	$21.68M	$570K	N/A	30
ALLR Allarity Therapeutics	2.4131 of 5 stars	$1.32 -2.9%	$10.25 +676.5%	+23.8%	$21.00M	$320K	N/A	10

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CDT) was last updated on 6/25/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CDT Equity (CDT) Competitors

CDT vs. ALVR, QUCY, VYNE, ALLR, and LPCN

How does CDT Equity compare to AlloVir?

Summary

How does CDT Equity compare to Mainz Biomed?

Summary

How does CDT Equity compare to VYNE Therapeutics?

Summary

How does CDT Equity compare to Allarity Therapeutics?

Summary

How does CDT Equity compare to Lipocine?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CDT vs. The Competition

CDT Equity Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CDT Equity (CDT) Competitors

CDT vs. ALVR, QUCY, VYNE, ALLR, and LPCN

How does CDT Equity compare to AlloVir?

Do institutionals and insiders believe in CDT or ALVR?

Is CDT or ALVR more profitable?

Does the media refer more to CDT or ALVR?

Which has more volatility & risk, CDT or ALVR?

Do analysts prefer CDT or ALVR?

Which has higher earnings & valuation, CDT or ALVR?

Summary

How does CDT Equity compare to Mainz Biomed?

Do analysts rate CDT or QUCY?

Does the media favor CDT or QUCY?

Is CDT or QUCY more profitable?

Which has more risk & volatility, CDT or QUCY?

Which has higher earnings and valuation, CDT or QUCY?

Do institutionals and insiders believe in CDT or QUCY?

Summary

How does CDT Equity compare to VYNE Therapeutics?

Do insiders and institutionals believe in CDT or VYNE?

Do analysts rate CDT or VYNE?

Which has more risk and volatility, CDT or VYNE?

Which has stronger valuation and earnings, CDT or VYNE?

Does the media refer more to CDT or VYNE?

Is CDT or VYNE more profitable?

Summary

How does CDT Equity compare to Allarity Therapeutics?

Which has more volatility & risk, ALLR or CDT?

Which has preferable valuation and earnings, ALLR or CDT?

Do institutionals & insiders have more ownership in ALLR or CDT?

Does the media favor ALLR or CDT?

Is ALLR or CDT more profitable?

Do analysts prefer ALLR or CDT?

Summary

How does CDT Equity compare to Lipocine?

Which has more volatility and risk, CDT or LPCN?

Do analysts prefer CDT or LPCN?

Do insiders and institutionals hold more shares of CDT or LPCN?

Does the media favor CDT or LPCN?

Is CDT or LPCN more profitable?

Which has better valuation and earnings, CDT or LPCN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CDT vs. The Competition

CDT Equity Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools